Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation.

ABSTRACT:

Introduction

Selective inhibitors of BRAF, vemurafenib and dabrafenib are the standard of care for metastatic melanoma patients with BRAF V600, while chemotherapy continued to be widely used in BRAF wild type patients.

Materials and methods

In order to discover novel candidate biomarkers predictive to treatment, serum of 39 metastatic melanoma vemurafenib (n = 19) or chemotherapy (n = 20) treated patients at baseline, at disease control and at progression, were analyzed using SELDI-TOF technology. In silico analysis was used to identify more significant peaks.

Results

In patients with different BRAF status, we found 5 peptides significantly deregulated, with the down-regulation of the m/z 9176 peak strongly associated with BRAF mutation. At baseline as predictive biom

SUBMITTER: Garrisi VM 

PROVIDER: S-EPMC4249853 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature